JP2010503625A5 - - Google Patents

Download PDF

Info

Publication number
JP2010503625A5
JP2010503625A5 JP2009527720A JP2009527720A JP2010503625A5 JP 2010503625 A5 JP2010503625 A5 JP 2010503625A5 JP 2009527720 A JP2009527720 A JP 2009527720A JP 2009527720 A JP2009527720 A JP 2009527720A JP 2010503625 A5 JP2010503625 A5 JP 2010503625A5
Authority
JP
Japan
Prior art keywords
ylcarbamoyl
hydroxy
amino
phenylethyl
benzimidazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009527720A
Other languages
English (en)
Japanese (ja)
Other versions
JP5249226B2 (ja
JP2010503625A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2007/007613 external-priority patent/WO2008031509A1/de
Publication of JP2010503625A publication Critical patent/JP2010503625A/ja
Publication of JP2010503625A5 publication Critical patent/JP2010503625A5/ja
Application granted granted Critical
Publication of JP5249226B2 publication Critical patent/JP5249226B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009527720A 2006-09-13 2007-08-31 凝固第ＩＸａ因子インヒビターとしての使用のためのイソセリン誘導体 Expired - Fee Related JP5249226B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102006042926 2006-09-13
DE102006042926.5 2006-09-13
PCT/EP2007/007613 WO2008031509A1 (de) 2006-09-13 2007-08-31 Isoserinderivate als inhibitoren des koagulationsfaktors ixa

Publications (3)

Publication Number Publication Date
JP2010503625A JP2010503625A (ja) 2010-02-04
JP2010503625A5 true JP2010503625A5 (enExample) 2010-09-30
JP5249226B2 JP5249226B2 (ja) 2013-07-31

Family

ID=38847022

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009527720A Expired - Fee Related JP5249226B2 (ja) 2006-09-13 2007-08-31 凝固第ＩＸａ因子インヒビターとしての使用のためのイソセリン誘導体

Country Status (22)

Country Link
US (1) US8097758B2 (enExample)
EP (1) EP2069289B1 (enExample)
JP (1) JP5249226B2 (enExample)
KR (1) KR20090050081A (enExample)
CN (1) CN101516834B (enExample)
AR (1) AR063708A1 (enExample)
AU (1) AU2007297013B2 (enExample)
BR (1) BRPI0716991A2 (enExample)
CA (1) CA2663544A1 (enExample)
CL (1) CL2007002652A1 (enExample)
IL (1) IL197504A (enExample)
MA (1) MA30707B1 (enExample)
MX (1) MX2009002047A (enExample)
MY (1) MY150745A (enExample)
NO (1) NO20091110L (enExample)
NZ (1) NZ575603A (enExample)
RU (1) RU2446157C2 (enExample)
SG (1) SG174080A1 (enExample)
TW (1) TWI394570B (enExample)
UY (1) UY30585A1 (enExample)
WO (1) WO2008031509A1 (enExample)
ZA (1) ZA200900807B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003078448A1 (en) 2002-03-13 2003-09-25 Signum Biosciences, Inc. Modulation of protein methylation and phosphoprotein phosphate
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
WO2006084033A1 (en) 2005-02-03 2006-08-10 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
US8383636B2 (en) * 2006-09-07 2013-02-26 Industrial Research Limited Acyclic amine inhibitors of 5-methytioadenosine phosphorylase and nucleosidase
CN102014897B (zh) 2008-04-21 2015-08-05 西格纳姆生物科学公司 化合物、组合物和其制备方法
AU2009322342A1 (en) 2008-12-05 2011-06-30 Merck Sharp & Dohme Corp. Morpholinone compounds as factor IXa inhibitors
EP2473491B1 (en) * 2009-08-31 2013-07-17 Mochida Pharmaceutical Co., Ltd. Morpholinone compounds as factor ixa inhibitors
WO2015160636A1 (en) 2014-04-16 2015-10-22 Merck Sharp & Dohme Corp. Factor ixa inhibitors
CN109627218B (zh) * 2018-11-27 2022-03-29 深圳市龙华区中心医院 一种抗凝小分子化合物及其应用和包含其的药物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4238260A1 (de) 1992-11-12 1994-05-19 Basf Ag Substituierte ortho-Ethenylphenylessigsäurederivate
WO1994022885A1 (en) * 1993-03-29 1994-10-13 Queen's University At Kingston Anticoagulant compounds
TW394760B (en) * 1993-09-07 2000-06-21 Hoffmann La Roche Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same
US6297269B1 (en) * 1995-06-06 2001-10-02 Pfizer Inc. Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors
MX9709875A (es) * 1995-06-06 1998-03-31 Pfizer N-(indol-2-carbonil)-glicinamidas substituidas y derivados como inhibidores de glicogeno fosforilasa, composiciones que las contienen y uso de las mismas.
BR9814340B1 (pt) * 1997-12-24 2010-07-13 compostos derivados de indol, processo para a preparação dos mesmo e composição farmacêutica.
US6451832B2 (en) * 1999-12-23 2002-09-17 Boehringer Ingelheim Pharma Kg Benzimidazoles with antithrombotic activity
CO5271699A1 (es) * 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
JP4666440B2 (ja) * 2000-06-30 2011-04-06 生化学工業株式会社 アミノアルコール誘導体
EP1332131A2 (en) 2000-11-07 2003-08-06 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
US7122559B2 (en) 2003-02-11 2006-10-17 Bristol-Myers Squibb Company Phenylglycine derivatives useful as serine protease inhibitors
US7056932B2 (en) * 2003-12-19 2006-06-06 Hoffman-La Roche Inc. Heterocyclyl substituted 1-alkoxy acetic acid amides
CN101253152A (zh) * 2005-09-02 2008-08-27 安斯泰来制药株式会社 作为rock抑制剂的酰胺衍生物
WO2007029587A1 (ja) * 2005-09-05 2007-03-15 Dainippon Sumitomo Pharma Co., Ltd. βセクレターゼ阻害剤

Similar Documents

Publication Publication Date Title
RU2009113602A (ru) Изосериновые производные для применения в качестве ингибиторов фактора свертывания крови ixa
CA2552050C (en) Substituted heterocycles and the uses thereof
JP6401773B2 (ja) Ｂｅｔブロモドメイン阻害剤およびこれを用いる治療方法
TWI480272B (zh) 藉由５，６－二氫－１ｈ－吡啶－２－酮與一或多種其他抗病毒化合物的組合物抑制ｃ型肝炎病毒的方法
RU2014131390A (ru) ПРОИЗВОДНЫЕ ТИЕНО[3,2-d]ПИРИМИДИНА, ОБЛАДАЮЩИЕ ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ ПРОТЕИНКИНАЗ
JP2009509989A5 (enExample)
AU2013216935B2 (en) Heteroaryl compounds and methods of use thereof
RU2005122447A (ru) Энантиомеры производных тиофенгидроксамовой кислоты и их применение в качестве ингибиторов гдац
CA2360233A1 (en) Methods of treating c1s-mediated diseases and conditions, and compounds and compositions therefor
WO2006115452A1 (en) Use of pyrazolyl-pyrimidine derivatives in the treatment of pain
JP2004536869A5 (enExample)
CN101137651A (zh) 哒嗪酮化合物
US20080039377A1 (en) Composition Comprising a Jnk Inhibitor and Cyclosporin
KR20080059283A (ko) 뇌 순환 장애의 예방 및 치료를 위한 치환된옥사졸리디논을 포함하는 조합요법
JP2010503624A5 (enExample)
EP3253749B1 (en) Compounds with anti-tumoral activity
AR070441A1 (es) Clorotiofeno - amidas como inhibidores de los factores de coagulacion xa y trombina
TW200404062A (en) Imidazolamino compounds
JP2010120974A5 (enExample)
JP2009511516A5 (enExample)
BR112021004371A2 (pt) terapia em combinação com um inibidor de fosfoinositídeo 3-quinase com uma porção de ligação a zinco
CA2967185A1 (en) Long acting pharmaceutical compositions for hepatitis c
JP2008527013A5 (enExample)
CN105017056B (zh) 苯基丙烯酮衍生物及其制法和药物组合物与用途
EP3013333B1 (en) Heterocyclic compounds and methods of use thereof for the treatment of hepatitis c